Cutaneous Squamous Cell Carcinoma
79
20
36
18
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
11.4%
9 terminated out of 79 trials
66.7%
-19.8% vs benchmark
3%
2 trials in Phase 3/4
56%
10 of 18 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 18 completed trials
Clinical Trials (79)
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
Cutaneous Squamous Cell Carcinoma Staging Study
ctDNA in Cutaneous Squamous Cell Carcinoma
FLASH Radiotherapy for Skin Cancer
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
TIL Therapy in cSCC and MCC
Ex Vivo Cutaneous SCC
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
Thermotherapy in Addition to SOC Palliative Radiotherapy